IMNM insider ownership: who sold, why, and what they still hold

What stands out

Philip Wagenheim sold $1.3M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Mar 20, 2026

Three insiders bought shares: Clay Siegall (37K shares, $750K), Jean Bienaime (18K shares, $351K) and Philip Tsai (10K shares, $205K).Clay Siegall: purchase, Mar 27, 2026 · Jean Bienaime: purchase, Jun 5, 2026 · Philip Tsai: purchase, Dec 19, 2025

A share of stake is shown for 0 of the 7 officers and directors who sold. 13 are left out

Left out: Clay Siegall, Philip Wagenheim, Isaac Barchas, Max Rosett, Jack Higgins, Jean Bienaime, Philip Tsai, Robert Lechleider, Sandra Stoneman, James Boylan, Carol Schafer, Kinney Horn and Sandra Swain (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Isaac Barchas

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.6MDisclosed plan

Max Rosett

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.5MDisclosed plan

Robert Lechleider

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.3MDisclosed plan

Kinney Horn

Chief Business Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.3MDisclosed plan

Philip Wagenheim

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.3MNo plan disclosed

All 7 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 11, 2026Jack Higgins sold 13K shares ($334K) under a disclosed trading plan. 18K shares came in from vesting or option exercises the same day, so the holding fell by 4K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Jack Higgins Chief Scientific Officer	13,200	$25.32	n/a	n/a	Sep 11, 2026	Sep 15, 2026

Outside holders, reported separately

Isaac Barchas (for the outside shareholder represented on the board) sold $9.6M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Immunome Inc. CEO selling stock?

No. Clay Siegall reported no open-market sales in the past 12 months.

Why are Immunome Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 91% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 9% had no disclosed plan. A trading plan schedules sales in advance.

Are any Immunome Inc. insiders buying?

Yes. 3 officers or directors reported 10 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold7 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Isaac Barchas Director	$8.6M 394K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Max Rosett Chief Financial Officer	$2.5M 125K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Robert Lechleider Chief Medical Officer	$2.3M 110K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Kinney Horn Chief Business Officer	$2.3M 92K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Philip Wagenheim Director	$1.3M 65K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Jack Higgins Chief Scientific Officer	$538K 23K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jean Bienaime Director	$204K 11K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

Board members representing outside shareholders, reported separately: Isaac Barchas (the shareholder sold $9.6M). Details

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Clay Siegall

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Clay Siegall are complete.

President and CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Clay Siegall

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Clay Siegall are complete; balances and unit counts will be added when the check is finished.

−200Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
800,000	$12.92	Aug 8, 2034	$9.9M
800,000	$10.60	Jul 28, 2035	$11.8M
360,000	$22.01	Jul 22, 2036	$1.2M

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Philip Wagenheim

Director

n/a

−65K

n/a

Vesting, gifts, unvested awards and holding lines for Philip Wagenheim

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Philip Wagenheim are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,333	$16.04	Jun 12, 2034	$105K
18,864	$9.57	Jun 9, 2035	$297K
9,897	$18.16	Jun 9, 2036	$71K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Isaac Barchas

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Isaac Barchas are complete.

Director

n/a

−394K

n/a

Vesting, gifts, unvested awards and holding lines for Isaac Barchas

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Isaac Barchas are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41,538	$8.73	Oct 26, 2033	$689K
11,333	$16.04	Jun 12, 2034	$105K
18,864	$9.57	Jun 9, 2035	$297K
9,897	$18.16	Jun 9, 2036	$71K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Max Rosett

Chief Financial Officer

n/a

−125K

n/a

Vesting, gifts, unvested awards and holding lines for Max Rosett

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Max Rosett are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
175,000	$16.57	Jan 30, 2034	$1.5M
30,000	$14.40	May 15, 2034	$328K
190,000	$12.92	Aug 8, 2034	$2.4M
207,000	$10.60	Jul 28, 2035	$3.0M
94,500	$22.01	Jul 22, 2036	$313K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Jack Higgins

Chief Scientific Officer

n/a

−23K

n/a

Vesting, gifts, unvested awards and holding lines for Jack Higgins

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jack Higgins are complete; balances and unit counts will be added when the check is finished.

−15Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
179,040	$1.35	Jun 23, 2032	$4.3M
200,000	$7.80	Nov 30, 2033	$3.5M
190,000	$12.92	Aug 8, 2034	$2.4M
151,840	$1.35	Jun 23, 2032	$3.6M
196,000	$10.60	Jul 28, 2035	$2.9M
76,500	$22.01	Jul 22, 2036	$253K
133,840	$1.35	Jun 23, 2032	$3.2M

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Jean Bienaime

Director

n/a

−11K

n/a

Vesting, gifts, unvested awards and holding lines for Jean Bienaime

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jean Bienaime are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
40,696	$8.91	Nov 6, 2033	$668K
11,333	$16.04	Jun 12, 2034	$105K
18,864	$9.57	Jun 9, 2035	$297K
9,897	$18.16	Jun 9, 2036	$71K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Philip Tsai

Chief Technical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Philip Tsai

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Philip Tsai are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
250,000	$13.15	Jun 16, 2034	$3.0M
190,000	$10.60	Jul 28, 2035	$2.8M
76,500	$22.01	Jul 22, 2036	$253K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Robert Lechleider

Chief Medical Officer

n/a

−110K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Lechleider

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Lechleider are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
400,000	$8.73	Oct 26, 2033	$6.6M
200,000	$12.92	Aug 8, 2034	$2.5M
242,000	$10.60	Jul 28, 2035	$3.6M
290,000	$8.73	Oct 26, 2033	$4.8M
108,000	$22.01	Jul 22, 2036	$357K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Sandra Stoneman

Chief Legal Officer & GC

n/a

Vesting, gifts, unvested awards and holding lines for Sandra Stoneman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Stoneman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
200,000	$16.57	Jan 30, 2034	$1.8M
210,000	$12.92	Aug 8, 2034	$2.6M
190,000	$10.60	Jul 28, 2035	$2.8M
76,500	$22.01	Jul 22, 2036	$253K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

James Boylan

Director

n/a

Vesting, gifts, unvested awards and holding lines for James Boylan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Boylan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41,538	$8.73	Oct 26, 2033	$689K
11,333	$16.04	Jun 12, 2034	$105K
18,864	$9.57	Jun 9, 2035	$297K
9,897	$18.16	Jun 9, 2036	$71K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Carol Schafer

Director

n/a

Vesting, gifts, unvested awards and holding lines for Carol Schafer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carol Schafer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,934	$11.01	Jan 1, 2034	$471K
11,333	$16.04	Jun 12, 2034	$105K
18,864	$9.57	Jun 9, 2035	$297K
9,897	$18.16	Jun 9, 2036	$71K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Kinney Horn

Chief Business Officer

n/a

−92K

n/a

Vesting, gifts, unvested awards and holding lines for Kinney Horn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kinney Horn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
300,000	$23.00	Feb 19, 2034	$696K
130,000	$12.92	Aug 8, 2034	$1.6M
120,750	$10.60	Jul 28, 2035	$1.8M
78,542	$12.92	Aug 8, 2034	$974K
62,500	$22.01	Jul 22, 2036	$207K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Sandra Swain

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sandra Swain

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Swain are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,737	$14.26	Apr 24, 2034	$285K
11,333	$16.04	Jun 12, 2034	$105K
18,864	$9.57	Jun 9, 2035	$297K
9,897	$18.16	Jun 9, 2036	$71K

Estimate: options held × ($25.32 − strike price), using the most recent insider trade price on Form 4 (Sep 11, 2026), not a market close.

Holdings and share of stake for Immunome Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$17.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $17.9M across 819,094 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $16.3M · 91%

The lighter segment is sales with no plan disclosed in the filing ($1.5M), including tax-related sales outside a plan.

No plan disclosed · $1.5M

Sales with no 10b5-1 plan and no tax reference in the filing. $1.3M of it is Philip Wagenheim. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Philip Wagenheim, Mar 20, 2026

Purchases · 3 buyers (10 trades)

3 officers and directors bought shares in this period, in 10 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 25 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Isaac Barchas Director	394K	$8.6M	100%	48%	Dec 22, 2025 to Aug 12, 2026
Max Rosett Chief Financial Officer	125K	$2.5M	100%	14%	Apr 2, 2026 to Jun 15, 2026
Robert Lechleider Chief Medical Officer	110K	$2.3M	100%	13%	Jun 25, 2026 to Jul 2, 2026
Kinney Horn Chief Business Officer	92K	$2.3M	100%	13%	Jul 7, 2026 to Aug 4, 2026
Philip Wagenheim Director	65K	$1.3M	0%	7%	Mar 20, 2026 to Mar 23, 2026
Jack Higgins Chief Scientific Officer	23K	$538K	100%	3%	Apr 2, 2026 to Sep 11, 2026
Jean Bienaime Director	11K	$204K	0%	1%	Jun 5, 2026 to Jun 5, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$8.3M	$8.3M	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$1.3M	$0	$0	$1.3M
Apr 2026	$1.6M	$1.6M	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$2.4M	$2.2M	$0	$204K
Jul 2026	$1.3M	$1.3M	$0	$0
Aug 2026	$2.6M	$2.6M	$0	$0
Sep 2026	$334K	$334K	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 16, 2025	Sold	Held Oct 16, 2026	Still held
Isaac Barchas ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Isaac Barchas are complete. Director	n/a	−410K	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Isaac Barchas Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Isaac Barchas are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $17.9M sold, after almost none in the past 5 years. 7 insiders sold; the average is 0 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	819K	7	$17.9M
Oct 16, 2025 1 year earlier	0	0	$0
Oct 16, 2024 2 years earlier	18K	2	$279K
Oct 17, 2023 3 years earlier	0	0	$0
Oct 17, 2022 4 years earlier	0	0	$0
Oct 17, 2021 5 years earlier	0	0	$0

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Immunome Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology187 filings on record, 37 filed in the 12-month period, and how we read them

All 187 Forms 3, 4 and 5 on record for Immunome Inc. (SEC CIK 1472012), filed from Oct 1, 2020 to Sep 15, 2026; 37 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (17)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Bruce Turner	Aug 13, 2024	42,300 shares, last reported balance as of Oct 2, 2023
Bob Lapetina	Jan 4, 2024	12,047 shares, last reported balance as of Jan 2, 2024
Phil Roberts	Dec 15, 2023	No balance on record
Franklyn Prendergast	Oct 4, 2023	60,840 shares, last reported balance as of Oct 2, 2023
Michael Rapp	Oct 3, 2023	2,244,384 shares, last reported balance as of Oct 2, 2023
Richard Baron	Jun 12, 2023	2,343 shares, last reported balance as of Aug 18, 2021
John Lamattina	Jun 12, 2023	66,953 shares, last reported balance as of Jan 15, 2023
Michael Lefenfeld	Jun 12, 2023	40,747 shares, last reported balance as of Jan 15, 2023
Purnanand Sarma	Jun 12, 2023	10,500 shares, last reported balance as of May 25, 2021
Dennis Giesing	Jun 12, 2023	No balance on record
Corleen Roche	Jun 12, 2023	No balance on record
Matthew Robinson	Jun 12, 2023	No balance on record
Michael Widlitz	Jun 1, 2021	51,315 shares, last reported balance as of Oct 6, 2020
Diane Marcou	Dec 10, 2020	No balance on record
Wistar Morris III	Oct 8, 2020	920,939 shares, last reported balance as of Oct 6, 2020
Richard Fitzgerald	Oct 5, 2020	No balance on record
Michael Morin	Oct 1, 2020	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Immunome Inc. insiders sold $17.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Immunome Inc. CEO selling stock?

Why are Immunome Inc. insiders selling?

Are any Immunome Inc. insiders buying?

The evidence

No plan disclosed · $1.5M

Purchases · 3 buyers (10 trades)

Sales by month